Neomorphic s Drug Discovery Efforts Halted; Affy Needs Bioinformatics | GenomeWeb

Neomorphic, which entered the genomics scene back in 1996 as a software company, tried earlier this year to refashion itself as a drug discovery company. But its new owner, Affymetrix of Santa Clara, Calif., is not going to let that happen. At least not right away.

Affymetrix, which last week bought Neomorphic for an eye-popping $70 million in stock, plans to use Neomorphic’s armory of leading bioinformaticists to help develop tools and generate data that will help Affymetrix’s GeneChip microarray technology to stay ahead of the competition.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.